Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 943-954

  Salem, Heba F ^a  

^a Beni Suef University   (Egypt)

Author keywords

Nanosuspension; Ovariectomized female rats; Progesterone; Thermosensitive gel

Indexed keywords

PROGESTERONE; NANOPARTICLE; POLOXAMER; STEARIC ACID; STEARIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; FEMALE; HEAT SENSITIVITY; IN VITRO STUDY; IN VIVO STUDY; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; RAT; SUSPENSION; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; BLOOD; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STABILITY; FLOW KINETICS; GEL; INTRAMUSCULAR DRUG ADMINISTRATION; OVARIECTOMY; SCANNING ELECTRON MICROSCOPY; SPRAGUE DAWLEY RAT; TEMPERATURE; ULTRASTRUCTURE;

RATTUS;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; FEMALE; GELS; INJECTIONS, INTRAMUSCULAR; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; OVARIECTOMY; POLOXAMER; PROGESTERONE; RATS; RATS, SPRAGUE-DAWLEY; RHEOLOGY; STEARIC ACIDS; TEMPERATURE;

EID: 79954481950     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S12947     Document Type: Article

References (45)

1. Fahraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest. 1983;13(6):447-453.
2. Ottoson UB, Carlstrom K, Damber JE, von Schoultz B. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration. Br J Obstet Gynaecol. 1984;91(11):1111-1119.
3. Knopp RH. Cardiovascular effects of endogenous and exogenous sex hormones over a woman's lifetime. Am J Obstet Gynecol. 1988;158 (6 Pt 2):1630-1643.
4. Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol. 1992;211(2):163-167.
5. Nillius SJ, Johansson ED. Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone. Am J Obstet Gynecol. 1971;110(4):470-477.
6. Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update. 2000;6(2):139-148.
7. Roman E, Aytoz A, Smitz JE, et al. Analysis of the bleeding pattern in assisted reproduction cycles with luteal phase supplementation using vaginal micronized progesterone. Hum Reprod. 2000;15(7):1435-1439.
8. Chen X, Young TJ, Sarkari M, Williams RO 3rd, Johnston KP. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm. 2002;242(1-2):3-14.
9. Zili Z, Sfar S, Fessi H. Preparation and characterization of poly-epsiloncaprolactone nanoparticles containing griseofulvin. Int J Pharm. 2005;294(1-2):261-267.
10. Zhang X, Xia Q, Gu N. Preparation of All-Trans Retinoic Acid nanosuspensions using a modified precipitation method. Drug Dev Ind Pharm. 2006;32(7):857-863.
11. van Eerdenbrugh B, van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364(1):64-75.
12. Kayser O, Olbrich C, Yardley V, Kiderlen AF, Croft SL. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm. 2003;254(1):73-75.
13. Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002;19(2):189-194.
14. Peters K, Leitzke S, Diederichs JE, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000;45(1):77-83.
15. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340(1-2):126-133.
16. Trotta M, Gallarate M, Pattarino F, Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Control Release. 2001;76(1-2):119-128.
17. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 2005;299(1-2):167-177.
18. Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm. 2009;369(1-2):136-143.
19. Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res. 1992;9(3):425-434.
20. Katakam M, Bell LN, Banga AK. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci. 1995;84(6):713-716.
21. Wenzel JG, Balaji KS, Koushik K, et al. Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Release. 2002;85(1-3):51-59.
22. Bhardwaj R, Blanchard J. Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407. J Pharm Sci. 1996;85(9):915-919.
23. Flores A, Gallegos AI, Velasco J, et al. The acute effects of bilateral ovariectomy or adrenalectomy on progesterone, testosterone, and estradiol serum levels depend on the surgical approach and the day of the estrous cycle when they are performed. Reprod Biol Endocrinol. 2008;6:48.
24. Paget GE, Barnes JM. Toxicity tests. In: Lautrance DR, Bacharach AL, editors. Evaluation of Drug Activities and Pharmacometrics. New York, NY: Academic Press; 1964:135-166.
25. Beck LR, Cowsar DR, Lewis DH, et al. A new long-acting injectable microcapsule system for the administration of progesterone. Fertil Steril. 1979;31(5):545-551.
26. Jameela SR, Kumary TV, Lal AV, Jayakrishnan A. Progesterone-loaded chitosan microspheres: a long acting biodegradable controlled delivery system. J Control Release. 1998;52(1-2):17-24.
27. Wissing SA, Muller RH. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release. 2002;81(3):225-233.
28. Chien Y. Novel Drug Delivery Systems. 29th ed. New York, NY: Informa Healthcare; 1992.
29. Riddick TM. Control of Colloid Stability through Zeta Potential: With a Closing Chapter on its Relationship to Cardiovascular Disease. Philadelphia, PA: Livingston Publishing Company; 1968.
30. Attwood D, Collett JH, Tait CJ. The micellar properties of the poly (oxyethylene)-poly (oxypropylene) copolymer pluronic F127 in water and electrolyte solution. Int J Pharm. 1985;26(1-2):25-33.
31. Gou M, Li X, Dai M, et al. A novel injectable local hydrophobic drug delivery system: biodegradable nanoparticles in thermo-sensitive hydrogel. Int J Pharm. 2008;9(1-2):228-233.
32. Pisal SS, Paradkar AR, Mahadik KR, Kadam SS. Pluronic gels for nasal delivery of Vitamin B12. Part I: preformulation study. Int J Pharm. 2004;270(1-2):37-45.
33. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release. 2002;80(1-3):9-28.
34. El Laithy HM, El-Shaboury KM. The development of Cutina lipogels and gel microemulsion for topical administration of fluconazole. AAPS PharmSciTech. 2002;3(4):E35.
35. Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res. 1992;9(3):425-434.
36. Sonoda A, Nitta N, Ohta S, et al. Controlled release and antitumor effect of pluronic F127 mixed with cisplatin in a rabbit model. Cardiovasc Intervent Radiol. 2010;33(1):135-142.
37. Xuan JJ, Balakrishnan P, Oh DH, et al. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam. Int J Pharm. 2010; 395(1-2):317-323.
38. Deluca PP, Mehta RC, Hausberger AG, Thanoo BC. Biodegradable polyesters for drug and polypeptide delivery. In: El Nokaly MA, Piatt DM, Carpentier BA, editors. Polymeric Delivery Systems: Properties and Applications. Washington, DC: ACS Symposium Series American Chemical Society; 1993:53-79.
39. Mannino CA, South SM, Inturrisi CE, Quinones-Jenab V. Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. J Pain. 2005;6(12):809-816.
40. Arkaravichien W, Kendle KE. Critical progesterone requirement for maintenance of pregnancy in ovariectomized rats. J Reprod Fertil. 1990;90(1):63-70.
41. Harini C, Sainath SB, Reddy PS. Progesterone administration induces preimplantation embryonic loss in mice. Fertil Steril. 2009; 91(5 Suppl):2137-2141.
42. Pepe GJ, Rothchild I. A comparative study of serum progesterone levels in pregnancy and in various types of pseudopregnancy in the rat. Endocrinology. 1974;95(1):275-279.
43. Pepe GJ, Rothchild I. Serum progesterone levels in ovariectomized rats injected with progesterone and estrone: relation to pregnancy maintenance and growth of decidual tissue. Endocrinology 1973;93(5): 1193-1199.
44. Young E Jr, Domenech L, Ponte L, Quintana R, van Thillo G, Young G. P-570: pregnancy outcome after ART may be predicted by serum progesterone levels on the day of [beta] hCG testing. Fertil Steril. 2006;86(3):S346.
45. Feltenstein MW, See RE. Plasma progesterone levels and cocaineseeking in freely cycling female rats across the estrous cycle. Drug Alcohol Depend. 2007;89(2-3):183-189.